FDA Eases Real-World Evidence Use in Medical Device Applications
FDA
|
Contributed by: Kate Gamble
Summary
The U.S. Food and Drug Administration (FDA) has announced a policy change allowing real-world evidence (RWE) to be used in drug and medical device applications without the need for identifiable patient data. This shift, initially focused on medical devices, aims to enhance the review process by utilizing large datasets while protecting patient privacy, addressing past limitations that slowed RWE integration. Since 2016, RWE has been included in various drug applications but has seen stagnation in device approvals, indicating a need for updated regulatory frameworks. This new guidance represents a significant step forward, potentially increasing the volume and diversity of data used in regulatory decisions for healthcare professionals.
